Menu Search
Equities

Xenon Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XENEN:MEX

Xenon Pharmaceuticals Inc

Actions
  • Price (MXN)591.36
  • Today's Change-138.04 / -18.93%
  • Shares traded--
  • 1 Year change--
  • Beta0.9237
Data delayed at least 20 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

  • Revenue in USD (TTM)7.50m
  • Net income in USD-306.33m
  • Incorporated2000
  • Employees316.00
  • Location
    Xenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
  • Phone+1 (604) 484-3300
  • Fax+1 (604) 484-3450
  • Websitehttps://www.xenon-pharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.